BioWorld - Wednesday, December 24, 2025

BioWorld Science

Oct. 29, 2018

View Archived Issues

MedImmune initiates phase I study of MEDI-6570

Read More

89Bio launches to develop drug for NASH

Read More

France becomes first country to market baclofen preparation to reduce alcohol consumption

Read More

Boehringer Ingelheim initiates phase I study of BI-730460

Read More

Uniparental mice give insights into ESC imprinting

Read More

Dual ICOS/CD28 antagonist demonstrates efficacy in models of autoimmune disease

Read More

Single locus near SIM1 gene significantly associated with risk of erectile dysfunction

Read More

OT-1096, a novel immunoactivating molecule that shows efficacy in xenograft models of TNBC

Read More

Phase I U.S. data presented for KN-035 in patients with advanced solid tumors

Read More

Pfizer and Novartis collaborate to study NASH therapy combinations

Read More

ASP-5094 safe and well tolerated in patients with rheumatoid arthritis on methotrexate

Read More

Griffithsin intravaginal gel well tolerated in first-in-human trial

Read More

Opthea reports promising 12-week data from phase Ib study of OPT-302 in DME

Read More

Novo Nordisk reports PIONEER 8 topline results with oral semaglutide in type 2 diabetes

Read More

Phase II data presented for SEL-212 in symptomatic gout patients

Read More

Novartis reports year 2 data from brolucizumab phase III trials in wet AMD

Read More

Genentech presents data on faricimab and ranibizumab PDS in wet AMD

Read More

Aduro initiates phase I study of ADU-1604 in metastatic melanoma

Read More

New phase I trial evaluates TAK-981 in metastatic solid tumors or lymphomas

Read More

Qrumpharma develops inhaled agent for nontuberculous mycobacterial infections

Read More

Innovate demonstrates preclinical proof of concept for larazotide in NASH mouse model

Read More

New phase Ib/IIa study explores use of AG-019 for treatment of early-onset type 1 diabetes

Read More